Idarubicin
Idarubicin
Definition
A semisynthetic 4-demethoxy analogue of the antineoplastic anthracycline antibiotic daunorubicin. Idarubicin intercalates into DNA and interferes with the activity of topoisomerase II, thereby inhibiting DNA replication, RNA transcription and protein synthesis. Due to its high lipophilicity, idarubicin penetrates cell membranes more efficiently than other anthracycline antibiotic compounds.
Also known as (1S,3S)-3-Acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-6,11-dioxo-1-naphthacenyl-3-amino-2,3,6-trideoxy-alpha-L-hexopyranoside, (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione, 4-Demethoxydaunomycin, 4-Demethoxydaunorubicin, 4-DMDR, IDARUBICIN — per NCIT
Also identified as
- ATC L01DB06 per RXNORM
- NCIT NCIT:C562 per NCIT
- SCTID 108786002 per RXNORM
- SCTID 372539000 per RXNORM
- UNII ZRP63D75JW per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Acute myeloid leukemia | may treat | MEDRT · Public domain (U.S. Government work) |
| Breast neoplasm | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Bone marrow | may treat a disease of this organ | DERIVED · CC BY 4.0 |
1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.